Business
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain. The presentations include two posters supporting Atea’
About this update from Atea Pharmaceuticals, Inc.
[{"type":"image","alt":"Atea Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Atea Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":170,"url":"https://media.zenfs.com/en/globenewswire.com/ef3965acbb5b5bff1eabb7e1952ded30"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KXeoz412fc_7VPFgx2isiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ef3965acbb5b5bff1eabb7e1952ded30","width":300,"height":170},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/KXeoz412fc_7VPFgx2isiw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ef3965acbb5b5bff1eabb7e1952ded30","width":300,"height":170}},"lazy":false},{"type":"text","content":"BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.","length":445,"tagName":"p"},{"type":"text","content":"The presentations include two posters supporting Atea’s fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented and designated as a top poster presentation is preclinical data for AT-587, a proprietary oral nucleotide analog recently selected as the Company’s lead clinical candidate for the treatment of hepatitis E virus (HEV).","length":464,"tagName":"p"},{"type":"text","content":"Collectively, these presentations underscore Atea’s continued progress across its antiviral pipeline and highlight Atea’s focus on advancing potential new treatment options for patients with viral hepatitis.","length":207,"tagName":"p"},{"type":"text","content":"“We look forward to sharing new clinical study results at EASL that further support the differentiated target profile of the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea. “As we approach topline results from our...